4.6 Article

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)

Journal

VIRUSES-BASEL
Volume 14, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/v14010136

Keywords

human T-lymphotropic virus type 1; HTLV-1-associated myelopathy; prednisolone; methylprednisolone; randomized controlled trial

Categories

Funding

  1. Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development [20ek0109394, 21ek0109529]
  2. Ministry of Health, Labour and Welfare of Japan [19FC1007]

Ask authors/readers for more resources

This study found that corticosteroid therapy may have benefits for patients with HTLV-1-associated myelopathy.
Corticosteroids are most commonly used to treat HTLV-1-associated myelopathy (HAM); however, their clinical efficacy has not been tested in randomized clinical trials. This randomized controlled trial included 8 and 30 HAM patients with rapidly and slowly progressing walking disabilities, respectively. Rapid progressors were assigned (1:1) to receive or not receive a 3-day course of intravenous methylprednisolone in addition to oral prednisolone therapy. Meanwhile, slow progressors were assigned (1:1) to receive oral prednisolone or placebo. The primary outcomes were a composite of >= 1-grade improvement in the Osame Motor Disability Score or >= 30% improvement in the 10 m walking time (10 mWT) at week 2 for rapid progressors and changes from baseline in 10 mWT at week 24 for slow progressors. In the rapid progressor trial, all four patients with but only one of four without intravenous methylprednisolone achieved the primary outcome (p = 0.14). In the slow progressor trial, the median changes in 10 mWT were -13.8% (95% CI: -20.1--7.1; p < 0.001) and -6.0% (95% CI: -12.8-1.3; p = 0.10) with prednisolone and placebo, respectively (p for between-group difference = 0.12). Whereas statistical significance was not reached for the primary endpoints, the overall data indicated the benefit of corticosteroid therapy. (Registration number: UMIN000023798, UMIN000024085)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available